Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend interlude was relaxing enough that you had a chance to catch up with life and take a few deep breaths. Now, of course, what resembles the new routine — Zoom, Skype and the like — has predictably returned. So time to fortify ourselves with a delicious cup of stimulation, and we invite you to join us. After all, the neurons need as much help as they can get, yes? On that note, here are a few tidbits you can wash down. Hope all goes well today, and do stay safe. …

AstraZeneca (AZN) will make as many as 30 million doses of coronavirus vaccine available to the U.K. by September and has committed to delivering 100 million doses this year. And the U.K. will be the first country to get access to the vaccine should it be successful, Bloomberg News writes. The vaccine, which is being developed at the University of Oxford with $79 million of funding, is already being studied in humans and could reach late-stage trials by the middle of the year.


A Covid-19 vaccine developed by Moderna (MRNA) appears to generate an immune response similar to the response seen in people who have been infected by the virus and recovered, STAT notes. In a Phase I trial, eight patients who received two doses at the lowest and middle strengths tested — 25 and 100 micrograms — developed neutralizing antibodies at levels similar to people who had recovered from infection. The data were limited and from only a small number of participants in the trial, but are still likely to be seen as encouraging.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!